½ÃÀ庸°í¼­
»óǰÄÚµå
1472425

¼¼°èÀÇ ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® : ¼ºº°, ½Ã¼ú À¯Çüº°, ¼¿·ê¶óÀÌÆ® À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° Àü¸Á°ú ¿¹Ãø(2024-2031³â)

Global Cellulite Treatment Market Size, Share & Trends Analysis Report By Gender (Female and Male), By Procedure Type, By Cellulite Type, By End User (Clinics & Beauty Centers, Hospitals and Others), By Regional Outlook and Forecast, 2024 - 2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: KBV Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 257 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀå ±Ô¸ð´Â 2031³â±îÁö 54¾ï ´Þ·¯¿¡ ´ÞÇϸç, ¿¹Ãø ±â°£ Áß CAGR 10.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ³ªÀ̰¡ µé¸é¼­ ÇǺÎÀÇ Åº·Â°ú ź·ÂÀÌ ¶³¾îÁö°í ¼¿·ê¶óÀÌÆ®°¡ »ý±â±â ½±½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é 2030³â±îÁö 6¸í Áß 1¸íÀÌ 60¼¼ ÀÌ»óÀÌ µÉ °ÍÀ̶ó°í ÇÕ´Ï´Ù. ÀÌ ½ÃÁ¡¿¡¼­ 60¼¼ ÀÌ»ó Àα¸´Â ¾à 14¾ï ¸í¿¡ ´ÞÇÒ °ÍÀ̸ç, ÀÌ´Â 2020³â¿¡ ¿¹ÃøµÇ´Â 10¾ï ¸íÀ» Å©°Ô »óȸÇÏ´Â ¼öÄ¡ÀÔ´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Àα¸ Åë°èÇÐÀû Ãß¼¼·Î ÀÎÇØ ¼¿·ê¶óÀÌÆ® Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

±×·¯³ª ¼¿·ê¶óÀÌÆ® Ä¡·á ºñ¿ëÀº Ä¡·áÀÇ À¯Çü°ú ½Ã¼úÀÚ¿¡ µû¶ó Å©°Ô ´Þ¶óÁú ¼ö ÀÖ½À´Ï´Ù. ·¹ÀÌÀú Ä¡·á ¹× °íÁÖÆÄ Ä¡·á¿Í °°Àº °í±Þ ħ½ÀÀû Ä¡·á´Â ºñħ½ÀÀû ´ë¾Èº¸´Ù ´õ ºñ½Ô´Ï´Ù. µû¶ó¼­ È¿°úÀûÀÎ ¼¿·ê¶óÀÌÆ® Ä¡·áÀÇ ³ôÀº ºñ¿ëÀº ±× µµÀÔÀ» ¹æÇØÇÏ°í ½ÃÀå ¼ºÀåÀ» Á¦ÇÑ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ Àü¿°º´À¸·Î ÀÎÇØ ÀϺΠ¼ÒºñÀÚÀÇ Ä¡·á¸¦ ¹ÞÀ¸·Á´Â ÇൿÀÌ ´Ê¾îÁ³½À´Ï´Ù. °æÁ¦ ºÒÈ®½Ç¼º°ú ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ÀϺΠ»ç¶÷µéÀº »óȲÀÌ °³¼±µÉ ¶§±îÁö ¼¿·ê¶óÀÌÆ® Ä¡·á¸¦ Æ÷ÇÔÇÑ ¹Ì¿ë ½Ã¼úÀ» ¿¬±âÇß½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¿¬Àº ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õÀÇ ¸ÅÃâ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í, Ä¡·á¸¦ ¹ÞÀ¸·Á´Â ȯÀÚµéÀÇ ¹ß±æÀÌ ²÷±â´Â °á°ú¸¦ ÃÊ·¡Çß½À´Ï´Ù. ÀÌó·³ COVID-19´Â ½ÃÀå Àü¹Ý¿¡ °ÉÃÄ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • ½ÃÀåÀÇ Á¤ÀÇ
  • ¸ñÀû
  • ½ÃÀå ¹üÀ§
  • ¼¼ºÐÈ­
  • Á¶»ç ¹æ¹ý

Á¦2Àå ½ÃÀå ¿ä¾à

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®

Á¦3Àå ½ÃÀå °³¿ä

  • ¼­·Ð
    • °³¿ä
      • ½ÃÀå ±¸¼º°ú ½Ã³ª¸®¿À
  • ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎ
    • ½ÃÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
  • Porter's Five Forces ºÐ¼®

Á¦4Àå ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀå¿¡¼­ µµÀԵǰí ÀÖ´Â ÃÖ±Ù Àü·«

Á¦5Àå ¼¼°èÀÇ ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀå : ¼ºº°

  • ¼¼°èÀÇ ¿©¼º ½ÃÀå : Áö¿ªº°
  • ¼¼°èÀÇ ³²¼º ½ÃÀå : Áö¿ªº°

Á¦6Àå ¼¼°èÀÇ ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀå : ½Ã¼ú À¯Çüº°

  • ¼¼°èÀÇ ºñħ½À ½ÃÀå : Áö¿ªº°
  • ¼¼°èÀÇ ±¹¼Ò ½ÃÀå : Áö¿ªº°
  • ¼¼°èÀÇ Àúħ½À ½ÃÀå : Áö¿ªº°

Á¦7Àå ¼¼°èÀÇ ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀå : ¼¿·ê¶óÀÌÆ® À¯Çüº°

  • ¼¼°èÀÇ ¼ÒÇÁÆ® ¼¿·ê¶óÀÌÆ® ½ÃÀå : Áö¿ªº°
  • ¼¼°èÀÇ ÇÏµå ¼¿·ê¶óÀÌÆ® ½ÃÀå : Áö¿ªº°
  • ¼¼°èÀÇ ºÎÁ¾ ½ÃÀå : Áö¿ªº°

Á¦8Àå ¼¼°èÀÇ ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼¼°èÀÇ Å¬¸®´Ð¡¤¹Ì¿ë ¼¾ÅÍ ½ÃÀå : Áö¿ªº°
  • ¼¼°èÀÇ º´¿ø ½ÃÀå : Áö¿ªº°
  • ¼¼°èÀÇ ±âŸ ½ÃÀå : Áö¿ªº°

Á¦9Àå ¼¼°èÀÇ ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀå : ±¹°¡º°
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
      • ±âŸ ºÏ¹Ì
  • À¯·´
    • À¯·´ÀÇ ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀå : ±¹°¡º°
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ·¯½Ã¾Æ
      • ½ºÆäÀÎ
      • ÀÌÅ»¸®¾Æ
      • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀå : ±¹°¡º°
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • Çѱ¹
      • ½Ì°¡Æ÷¸£
      • ¸»·¹À̽þÆ
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀå : ±¹°¡º°
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ¾Æ¶ø¿¡¹Ì¸®Æ®
      • »ç¿ìµð¾Æ¶óºñ¾Æ
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • ³ªÀÌÁö¸®¾Æ
      • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ °³¿ä

  • Candela corporation(Syneron Medical)
  • Bausch Health Companies, Inc
  • Sinclair Pharma Ltd(Huadong Medicine Co., Ltd.)
  • AbbVie, Inc
  • Hologic, Inc
  • Galderma SA
  • Endo International PLC
  • Merz Pharma GmbH & Co KGaA
  • Cynosure, LLC(Clayton, Dubilier & Rice, LLC)
  • Zimmer MedizinSysteme GmbH

Á¦11Àå ¼¿·ê¶óÀÌÆ® Ä¡·á ½ÃÀåÀÇ ¼º°ø Çʼö Á¶°Ç

KSA 24.05.09

The Global Cellulite Treatment Market size is expected to reach $5.4 billion by 2031, rising at a market growth of 10.1% CAGR during the forecast period.

Using high-energy acoustic waves, a relatively new treatment option known as acoustic wave therapy targets and targets cellulite in order to break it down. This non-invasive treatment has been shown to improve the appearance of cellulite, reduce skin laxity, and improve overall skin texture. Consequently, the non-invasive would generate approximately 43.0 % share in the market by 2031. These treatments are more effective, safer, and more comfortable than traditional surgical procedures. As a result, more patients opt for these innovative treatments to achieve smoother, firmer, and more youthful-looking skin.

As more individuals become aware of cellulite's impact on their appearance and self-esteem, there has been a corresponding surge in the demand for effective treatments to address this common aesthetic concern. This heightened awareness has been fostered by major international bodies, organizations, and associations dedicated to promoting skin health and raising awareness about cellulite. Hence, the increasing awareness and concern about cellulite have driven the demand for cellulite treatments.

Additionally, As people age, their skin loses elasticity and firmness, making them more prone to cellulite. According to the World Health Organization, one in six people will be 60 or older by 2030. At this time, there will be approximately 1.4 billion people aged 60 or older, a significant increase over the 1 billion projected for 2020. Thus, this demographic trend has increased the demand for cellulite treatments.

However, Cellulite treatments can vary widely in cost depending on the type of treatment and the provider. More advanced or invasive procedures, such as laser therapy or radiofrequency treatments, are more expensive than non-invasive options. Thus, the high cost of effective cellulite treatments may deter their adoption, limiting the market's growth.

Furthermore, The pandemic led to a delay in treatment-seeking behavior among some consumers. Economic uncertainty and concerns about the virus caused some individuals to postpone cosmetic procedures, including cellulite treatments until the situation improves. This delay impacted providers' revenue and led to a backlog of patients seeking treatment. Thus, the pandemic had an overall negative impact on the market.

By Gender Analysis

Based on gender, the market is segmented into male and female. The male segment acquired a 27.05 % revenue share in the market in 2023. Men increasingly seek treatments to improve their appearance and address aesthetic concerns, including cellulite. Additionally, as the stigma surrounding cosmetic procedures diminishes, more men are exploring options to enhance their physical appearance, including reducing the appearance of cellulite. According to the gender breakouts for the 2022 American Society of Plastic Surgeons (ASPS) Procedural Statistics, men accounted for exceptional growth - a 207% rise in total cosmetic procedures since 2019.

By Procedure Type Analysis

On the basis of procedure type, the market is classified into non-invasive, minimally invasive, and topical. The non-invasive segment acquired the 44.14 % revenue share in the market in 2023. Patients are able to return to their regular activities almost immediately after receiving non-invasive treatments because these treatments typically require only a short period of downtime. This convenience attracts those with busy lifestyles who cannot afford extended recovery periods. As technology advances, non-invasive treatments are likely to become even more popular among those looking to improve the appearance of their skin.

By Cellulite Type Analysis

Based on cellulite type, the market is characterized into soft cellulite, hard cellulite, and edematous. The edematous segment procured a 15.47 % growth rate in the market in 2023. Edematous cellulite is a type of cellulite characterized by fluid retention and swelling in the affected areas. Hormonal imbalances, poor circulation, and lifestyle factors like diet and exercise are factors that are frequently associated with this condition. The demand for edematous cellulite treatment is on the rise, driven by several factors, including increasing awareness of cellulite as a common concern, the desire for smoother skin, and advancements in treatment options.

By End-User Analysis

By end user, the market is divided into hospitals, clinics & beauty centers, and others. The clinics & beauty centers segment witnessed the 52.27 % revenue share in the market in 2023. Aestheticians, dermatologists, and trained technicians are examples of the types of skilled professionals that are frequently employed by beauty centers and clinics that specialize in the treatment of cellulite. These professionals have extensive experience using these treatments. They may also offer complementary services, such as body contouring and skin tightening treatments, to enhance the results of cellulite reduction procedures.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment witnessed a 18.45 % growth rate in the market in 2023. Countries such as China, India, and Japan are driving market growth. These countries have large populations with increasing disposable income levels, leading to a growing demand for aesthetic procedures, including cellulite treatments. Additionally, the influence of Western beauty standards and the rise of social media contribute to the growing acceptance of cellulite treatments in these regions.

Recent Strategies Deployed in the Market

  • Jan-2024: Solta Medical, a subsidiary of Bausch Health Companies Inc., has received approval from China's National Medical Product Administration (NMPA) for its Thermage FLX and the TR-4 Return pad. These are non-invasive treatments utilizing radiofrequency technology aimed at tightening and enhancing the smoothness and texture of the skin's surface, ultimately optimizing a patient's appearance. Thermage proves versatile and effective, suitable for all skin types and genders, and applicable to various areas on the face, body, and around the eyes.
  • Mar-2023: Sinclair Pharma Ltd. has introduced a novel product called Lanluma, a collagen-stimulating injectable filler. Lanluma is designed to reshape, volumize, and enhance body contours. The minimally invasive treatment entails the injection of Poly-L-lactic acid (PLLA), which enhances skin tightness and texture, augments curves in flat or sagging buttocks, reduces cellulite and dimples, enhances buttock shape and volume, and addresses natural or post-surgical concerns like atrophy and lipoatrophy.
  • Feb-2023: Candela Corporation introduces its latest innovation, the Profound Matrix system, designed for radiofrequency-based skin treatments. This system employs radiofrequency microneedles to address skin concerns across various stages of the aging process. With features like Sublime, Sublative RF, and the new Matrix Pro applications, it provides bipolar radiofrequency treatment to improve the appearance of fine lines and wrinkles.
  • Aug-2022: Allergan Aesthetics, an AbbVie company, launches SkinMedica(R) Firm & Tone Lotion for Body, the inaugural product from its professional-grade skincare line. Formulated to combat visible signs of body skin aging, it addresses crepey skin, uneven texture, firmness, tone, and sagging. Featuring ingredients like Green Microalgae, Shitake Mushroom Extracts, Lemon Balm Extract, Coffea Arabica Seed Oil, Caffeine, Hydrolyzed Rice Protein, and Japanese Parsley, it supports various skin functions including dermal extracellular matrix components, cellular clearance and recycling, antioxidant protection, and balanced lipid metabolism.
  • Feb-2022: Sinclair Pharma Ltd. has entered into an agreement with Viora Ltd., a medical device company specializing in medical aesthetic systems. The agreement involves Sinclair's acquisition of Viora, enhancing Sinclair Cocoon's product range and extending its commercial footprint in the United States through various technologies.
  • Dec-2021: Allergan Aesthetics, a subsidiary of AbbVie Inc., has finalized the acquisition of Soliton, Inc., a medical device company specializing in acoustic shockwave technology for tattoo and cellulite removal. With this acquisition, the company seeks to enhance its solution portfolio by integrating a proven treatment for cellulite, complementing its existing range of non-invasive body contouring treatments.

List of Key Companies Profiled

  • Candela Corporation (Syneron Medical)
  • Bausch Health Companies, Inc.
  • Sinclair Pharma Ltd. (Huadong Medicine Co., Ltd.)
  • AbbVie, Inc.
  • Cynosure, LLC (Clayton, Dubilier & Rice, LLC)
  • Hologic, Inc.
  • Galderma S.A.
  • Zimmer MedizinSysteme GmbH
  • Endo International PLC
  • Merz Pharma GmbH & Co. KGaA

Global Cellulite Treatment Market Report Segmentation

By Gender

  • Female
  • Male

By Procedure Type

  • Non-invasive
  • Topical
  • Minimally Invasive

By Cellulite Type

  • Soft Cellulite
  • Hard Cellulite
  • Edematous

By End User

  • Clinics & Beauty Centers
  • Hospitals
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Table of Contents

Chapter 1.Market Scope & Methodology

  • 1.1Market Definition
  • 1.2Objectives
  • 1.3Market Scope
  • 1.4Segmentation
    • 1.4.1Global Cellulite Treatment Market, by Gender
    • 1.4.2Global Cellulite Treatment Market, by Procedure Type
    • 1.4.3Global Cellulite Treatment Market, by Cellulite Type
    • 1.4.4Global Cellulite Treatment Market, by End User
    • 1.4.5Global Cellulite Treatment Market, by Geography
  • 1.5Methodology for the research

Chapter 2.Market at a Glance

  • 2.1Key Highlights

Chapter 3.Market Overview

  • 3.1Introduction
    • 3.1.1Overview
      • 3.1.1.1Market Composition and Scenario
  • 3.2Key Factors Impacting the Market
    • 3.2.1Market Drivers
    • 3.2.2Market Restraints
    • 3.2.3Market Opportunities
    • 3.2.4Market Challenges
  • 3.3Porter's Five Forces Analysis

Chapter 4.Recent Strategies Deployed in Cellulite Treatment Market

Chapter 5.Global Cellulite Treatment Market by Gender

  • 5.1Global Female Market by Region
  • 5.2Global Male Market by Region

Chapter 6.Global Cellulite Treatment Market by Procedure Type

  • 6.1Global Non-invasive Market by Region
  • 6.2Global Topical Market by Region
  • 6.3Global Minimally Invasive Market by Region

Chapter 7.Global Cellulite Treatment Market by Cellulite Type

  • 7.1Global Soft Cellulite Market by Region
  • 7.2Global Hard Cellulite Market by Region
  • 7.3Global Edematous Market by Region

Chapter 8.Global Cellulite Treatment Market by End User

  • 8.1Global Clinics & Beauty Centers Market by Region
  • 8.2Global Hospitals Market by Region
  • 8.3Global Others Market by Region

Chapter 9.Global Cellulite Treatment Market by Region

  • 9.1North America Cellulite Treatment Market
    • 9.1.1North America Cellulite Treatment Market by Gender
      • 9.1.1.1North America Female Market by Region
      • 9.1.1.2North America Male Market by Region
    • 9.1.2North America Cellulite Treatment Market by Procedure Type
      • 9.1.2.1North America Non-invasive Market by Country
      • 9.1.2.2North America Topical Market by Country
      • 9.1.2.3North America Minimally Invasive Market by Country
    • 9.1.3North America Cellulite Treatment Market by Cellulite Type
      • 9.1.3.1North America Soft Cellulite Market by Country
      • 9.1.3.2North America Hard Cellulite Market by Country
      • 9.1.3.3North America Edematous Market by Country
    • 9.1.4North America Cellulite Treatment Market by End User
      • 9.1.4.1North America Clinics & Beauty Centers Market by Country
      • 9.1.4.2North America Hospitals Market by Country
      • 9.1.4.3North America Others Market by Country
    • 9.1.5North America Cellulite Treatment Market by Country
      • 9.1.5.1US Cellulite Treatment Market
        • 9.1.5.1.1US Cellulite Treatment Market by Gender
        • 9.1.5.1.2US Cellulite Treatment Market by Procedure Type
        • 9.1.5.1.3US Cellulite Treatment Market by Cellulite Type
        • 9.1.5.1.4US Cellulite Treatment Market by End User
      • 9.1.5.2Canada Cellulite Treatment Market
        • 9.1.5.2.1Canada Cellulite Treatment Market by Gender
        • 9.1.5.2.2Canada Cellulite Treatment Market by Procedure Type
        • 9.1.5.2.3Canada Cellulite Treatment Market by Cellulite Type
        • 9.1.5.2.4Canada Cellulite Treatment Market by End User
      • 9.1.5.3Mexico Cellulite Treatment Market
        • 9.1.5.3.1Mexico Cellulite Treatment Market by Gender
        • 9.1.5.3.2Mexico Cellulite Treatment Market by Procedure Type
        • 9.1.5.3.3Mexico Cellulite Treatment Market by Cellulite Type
        • 9.1.5.3.4Mexico Cellulite Treatment Market by End User
      • 9.1.5.4Rest of North America Cellulite Treatment Market
        • 9.1.5.4.1Rest of North America Cellulite Treatment Market by Gender
        • 9.1.5.4.2Rest of North America Cellulite Treatment Market by Procedure Type
        • 9.1.5.4.3Rest of North America Cellulite Treatment Market by Cellulite Type
        • 9.1.5.4.4Rest of North America Cellulite Treatment Market by End User
  • 9.2Europe Cellulite Treatment Market
    • 9.2.1Europe Cellulite Treatment Market by Gender
      • 9.2.1.1Europe Female Market by Country
      • 9.2.1.2Europe Male Market by Country
    • 9.2.2Europe Cellulite Treatment Market by Procedure Type
      • 9.2.2.1Europe Non-invasive Market by Country
      • 9.2.2.2Europe Topical Market by Country
      • 9.2.2.3Europe Minimally Invasive Market by Country
    • 9.2.3Europe Cellulite Treatment Market by Cellulite Type
      • 9.2.3.1Europe Soft Cellulite Market by Country
      • 9.2.3.2Europe Hard Cellulite Market by Country
      • 9.2.3.3Europe Edematous Market by Country
    • 9.2.4Europe Cellulite Treatment Market by End User
      • 9.2.4.1Europe Clinics & Beauty Centers Market by Country
      • 9.2.4.2Europe Hospitals Market by Country
      • 9.2.4.3Europe Others Market by Country
    • 9.2.5Europe Cellulite Treatment Market by Country
      • 9.2.5.1Germany Cellulite Treatment Market
        • 9.2.5.1.1Germany Cellulite Treatment Market by Gender
        • 9.2.5.1.2Germany Cellulite Treatment Market by Procedure Type
        • 9.2.5.1.3Germany Cellulite Treatment Market by Cellulite Type
        • 9.2.5.1.4Germany Cellulite Treatment Market by End User
      • 9.2.5.2UK Cellulite Treatment Market
        • 9.2.5.2.1UK Cellulite Treatment Market by Gender
        • 9.2.5.2.2UK Cellulite Treatment Market by Procedure Type
        • 9.2.5.2.3UK Cellulite Treatment Market by Cellulite Type
        • 9.2.5.2.4UK Cellulite Treatment Market by End User
      • 9.2.5.3France Cellulite Treatment Market
        • 9.2.5.3.1France Cellulite Treatment Market by Gender
        • 9.2.5.3.2France Cellulite Treatment Market by Procedure Type
        • 9.2.5.3.3France Cellulite Treatment Market by Cellulite Type
        • 9.2.5.3.4France Cellulite Treatment Market by End User
      • 9.2.5.4Russia Cellulite Treatment Market
        • 9.2.5.4.1Russia Cellulite Treatment Market by Gender
        • 9.2.5.4.2Russia Cellulite Treatment Market by Procedure Type
        • 9.2.5.4.3Russia Cellulite Treatment Market by Cellulite Type
        • 9.2.5.4.4Russia Cellulite Treatment Market by End User
      • 9.2.5.5Spain Cellulite Treatment Market
        • 9.2.5.5.1Spain Cellulite Treatment Market by Gender
        • 9.2.5.5.2Spain Cellulite Treatment Market by Procedure Type
        • 9.2.5.5.3Spain Cellulite Treatment Market by Cellulite Type
        • 9.2.5.5.4Spain Cellulite Treatment Market by End User
      • 9.2.5.6Italy Cellulite Treatment Market
        • 9.2.5.6.1Italy Cellulite Treatment Market by Gender
        • 9.2.5.6.2Italy Cellulite Treatment Market by Procedure Type
        • 9.2.5.6.3Italy Cellulite Treatment Market by Cellulite Type
        • 9.2.5.6.4Italy Cellulite Treatment Market by End User
      • 9.2.5.7Rest of Europe Cellulite Treatment Market
        • 9.2.5.7.1Rest of Europe Cellulite Treatment Market by Gender
        • 9.2.5.7.2Rest of Europe Cellulite Treatment Market by Procedure Type
        • 9.2.5.7.3Rest of Europe Cellulite Treatment Market by Cellulite Type
        • 9.2.5.7.4Rest of Europe Cellulite Treatment Market by End User
  • 9.3Asia Pacific Cellulite Treatment Market
    • 9.3.1Asia Pacific Cellulite Treatment Market by Gender
      • 9.3.1.1Asia Pacific Female Market by Country
      • 9.3.1.2Asia Pacific Male Market by Country
    • 9.3.2Asia Pacific Cellulite Treatment Market by Procedure Type
      • 9.3.2.1Asia Pacific Non-invasive Market by Country
      • 9.3.2.2Asia Pacific Topical Market by Country
      • 9.3.2.3Asia Pacific Minimally Invasive Market by Country
    • 9.3.3Asia Pacific Cellulite Treatment Market by Cellulite Type
      • 9.3.3.1Asia Pacific Soft Cellulite Market by Country
      • 9.3.3.2Asia Pacific Hard Cellulite Market by Country
      • 9.3.3.3Asia Pacific Edematous Market by Country
    • 9.3.4Asia Pacific Cellulite Treatment Market by End User
      • 9.3.4.1Asia Pacific Clinics & Beauty Centers Market by Country
      • 9.3.4.2Asia Pacific Hospitals Market by Country
      • 9.3.4.3Asia Pacific Others Market by Country
    • 9.3.5Asia Pacific Cellulite Treatment Market by Country
      • 9.3.5.1China Cellulite Treatment Market
        • 9.3.5.1.1China Cellulite Treatment Market by Gender
        • 9.3.5.1.2China Cellulite Treatment Market by Procedure Type
        • 9.3.5.1.3China Cellulite Treatment Market by Cellulite Type
        • 9.3.5.1.4China Cellulite Treatment Market by End User
      • 9.3.5.2Japan Cellulite Treatment Market
        • 9.3.5.2.1Japan Cellulite Treatment Market by Gender
        • 9.3.5.2.2Japan Cellulite Treatment Market by Procedure Type
        • 9.3.5.2.3Japan Cellulite Treatment Market by Cellulite Type
        • 9.3.5.2.4Japan Cellulite Treatment Market by End User
      • 9.3.5.3India Cellulite Treatment Market
        • 9.3.5.3.1India Cellulite Treatment Market by Gender
        • 9.3.5.3.2India Cellulite Treatment Market by Procedure Type
        • 9.3.5.3.3India Cellulite Treatment Market by Cellulite Type
        • 9.3.5.3.4India Cellulite Treatment Market by End User
      • 9.3.5.4South Korea Cellulite Treatment Market
        • 9.3.5.4.1South Korea Cellulite Treatment Market by Gender
        • 9.3.5.4.2South Korea Cellulite Treatment Market by Procedure Type
        • 9.3.5.4.3South Korea Cellulite Treatment Market by Cellulite Type
        • 9.3.5.4.4South Korea Cellulite Treatment Market by End User
      • 9.3.5.5Singapore Cellulite Treatment Market
        • 9.3.5.5.1Singapore Cellulite Treatment Market by Gender
        • 9.3.5.5.2Singapore Cellulite Treatment Market by Procedure Type
        • 9.3.5.5.3Singapore Cellulite Treatment Market by Cellulite Type
        • 9.3.5.5.4Singapore Cellulite Treatment Market by End User
      • 9.3.5.6Malaysia Cellulite Treatment Market
        • 9.3.5.6.1Malaysia Cellulite Treatment Market by Gender
        • 9.3.5.6.2Malaysia Cellulite Treatment Market by Procedure Type
        • 9.3.5.6.3Malaysia Cellulite Treatment Market by Cellulite Type
        • 9.3.5.6.4Malaysia Cellulite Treatment Market by End User
      • 9.3.5.7Rest of Asia Pacific Cellulite Treatment Market
        • 9.3.5.7.1Rest of Asia Pacific Cellulite Treatment Market by Gender
        • 9.3.5.7.2Rest of Asia Pacific Cellulite Treatment Market by Procedure Type
        • 9.3.5.7.3Rest of Asia Pacific Cellulite Treatment Market by Cellulite Type
        • 9.3.5.7.4Rest of Asia Pacific Cellulite Treatment Market by End User
  • 9.4LAMEA Cellulite Treatment Market
    • 9.4.1LAMEA Cellulite Treatment Market by Gender
      • 9.4.1.1LAMEA Female Market by Country
      • 9.4.1.2LAMEA Male Market by Country
    • 9.4.2LAMEA Cellulite Treatment Market by Procedure Type
      • 9.4.2.1LAMEA Non-invasive Market by Country
      • 9.4.2.2LAMEA Topical Market by Country
      • 9.4.2.3LAMEA Minimally Invasive Market by Country
    • 9.4.3LAMEA Cellulite Treatment Market by Cellulite Type
      • 9.4.3.1LAMEA Soft Cellulite Market by Country
      • 9.4.3.2LAMEA Hard Cellulite Market by Country
      • 9.4.3.3LAMEA Edematous Market by Country
    • 9.4.4LAMEA Cellulite Treatment Market by End User
      • 9.4.4.1LAMEA Clinics & Beauty Centers Market by Country
      • 9.4.4.2LAMEA Hospitals Market by Country
      • 9.4.4.3LAMEA Others Market by Country
    • 9.4.5LAMEA Cellulite Treatment Market by Country
      • 9.4.5.1Brazil Cellulite Treatment Market
        • 9.4.5.1.1Brazil Cellulite Treatment Market by Gender
        • 9.4.5.1.2Brazil Cellulite Treatment Market by Procedure Type
        • 9.4.5.1.3Brazil Cellulite Treatment Market by Cellulite Type
        • 9.4.5.1.4Brazil Cellulite Treatment Market by End User
      • 9.4.5.2Argentina Cellulite Treatment Market
        • 9.4.5.2.1Argentina Cellulite Treatment Market by Gender
        • 9.4.5.2.2Argentina Cellulite Treatment Market by Procedure Type
        • 9.4.5.2.3Argentina Cellulite Treatment Market by Cellulite Type
        • 9.4.5.2.4Argentina Cellulite Treatment Market by End User
      • 9.4.5.3UAE Cellulite Treatment Market
        • 9.4.5.3.1UAE Cellulite Treatment Market by Gender
        • 9.4.5.3.2UAE Cellulite Treatment Market by Procedure Type
        • 9.4.5.3.3UAE Cellulite Treatment Market by Cellulite Type
        • 9.4.5.3.4UAE Cellulite Treatment Market by End User
      • 9.4.5.4Saudi Arabia Cellulite Treatment Market
        • 9.4.5.4.1Saudi Arabia Cellulite Treatment Market by Gender
        • 9.4.5.4.2Saudi Arabia Cellulite Treatment Market by Procedure Type
        • 9.4.5.4.3Saudi Arabia Cellulite Treatment Market by Cellulite Type
        • 9.4.5.4.4Saudi Arabia Cellulite Treatment Market by End User
      • 9.4.5.5South Africa Cellulite Treatment Market
        • 9.4.5.5.1South Africa Cellulite Treatment Market by Gender
        • 9.4.5.5.2South Africa Cellulite Treatment Market by Procedure Type
        • 9.4.5.5.3South Africa Cellulite Treatment Market by Cellulite Type
        • 9.4.5.5.4South Africa Cellulite Treatment Market by End User
      • 9.4.5.6Nigeria Cellulite Treatment Market
        • 9.4.5.6.1Nigeria Cellulite Treatment Market by Gender
        • 9.4.5.6.2Nigeria Cellulite Treatment Market by Procedure Type
        • 9.4.5.6.3Nigeria Cellulite Treatment Market by Cellulite Type
        • 9.4.5.6.4Nigeria Cellulite Treatment Market by End User
      • 9.4.5.7Rest of LAMEA Cellulite Treatment Market
        • 9.4.5.7.1Rest of LAMEA Cellulite Treatment Market by Gender
        • 9.4.5.7.2Rest of LAMEA Cellulite Treatment Market by Procedure Type
        • 9.4.5.7.3Rest of LAMEA Cellulite Treatment Market by Cellulite Type
        • 9.4.5.7.4Rest of LAMEA Cellulite Treatment Market by End User

Chapter 10.Company Profiles

  • 10.1Candela corporation (Syneron Medical)
    • 10.1.1Company Overview
    • 10.1.2Recent strategies and developments:
      • 10.1.2.1Partnerships, Collaborations, and Agreements:
      • 10.1.2.2Product Launches and Product Expansions:
    • 10.1.3SWOT Analysis
  • 10.2Bausch Health Companies, Inc
    • 10.2.1Company Overview
    • 10.2.2Financial Analysis
    • 10.2.3Segmental and Regional Analysis
    • 10.2.4Research & Development Expense
    • 10.2.5Recent strategies and developments:
      • 10.2.5.1Trials and Approvals:
    • 10.2.6SWOT Analysis
  • 10.3Sinclair Pharma Ltd. (Huadong Medicine Co., Ltd.)
    • 10.3.1Company Overview
    • 10.3.2Recent strategies and developments:
      • 10.3.2.1Partnerships, Collaborations, and Agreements:
      • 10.3.2.2Product Launches and Product Expansions:
    • 10.3.3SWOT Analysis
  • 10.4AbbVie, Inc.
    • 10.4.1Company Overview
    • 10.4.2Financial Analysis
    • 10.4.3Regional Analysis
    • 10.4.4Research & Development Expense
    • 10.4.5Recent strategies and developments:
      • 10.4.5.1Product Launches and Product Expansions:
      • 10.4.5.2Acquisition and Mergers:
    • 10.4.6SWOT Analysis
  • 10.5Hologic, Inc.
    • 10.5.1Company Overview
    • 10.5.2Financial Analysis
    • 10.5.3Segmental and Regional Analysis
    • 10.5.4Research & Development Expenses
    • 10.5.5SWOT Analysis
  • 10.6Galderma S.A.
    • 10.6.1Company Overview
    • 10.6.2SWOT Analysis
  • 10.7Endo International PLC
    • 10.7.1Company Overview
    • 10.7.2Financial Analysis
    • 10.7.3Segmental Analysis
    • 10.7.4Research & Development Expense
    • 10.7.5Recent strategies and developments:
      • 10.7.5.1Trials and Approvals:
      • 10.7.5.2Acquisition and Mergers:
    • 10.7.6SWOT Analysis
  • 10.8Merz Pharma GmbH & Co. KGaA
    • 10.8.1Company Overview
    • 10.8.2SWOT Analysis
  • 10.9Cynosure, LLC (Clayton, Dubilier & Rice, LLC)
    • 10.9.1Company Overview
    • 10.9.2SWOT Analysis
  • 10.10.Zimmer MedizinSysteme GmbH
    • 10.10.1Company Overview
    • 10.10.2SWOT Analysis

Chapter 11.Winning Imperatives of Cellulite Treatment Market

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦